Effect of Efpeglenatide on Cardiovascular Outcomes

Last updated:
2026-07-11
Language and content disclaimer

The content and search results on this site are collected from or provided by third parties. As such some of the information may only be available in the language originally submitted by the sponsor of the trial. Learn more about the information on the search portal.

Linking to Non-Government of Canada Websites

Links to websites not under the control of the Government of Canada, including those to our social media accounts, and to clinical trial records in international registries are provided solely for the convenience of our website visitors. We are not responsible for the accuracy, currency or reliability of the content of such websites. The Government of Canada does not offer any guarantee in that regard and is not responsible for the information found through these links, nor does it endorse the sites and their content.

Visitors should also be aware that information offered by non-Government of Canada sites to which this website links is not subject to the Privacy Act or the Official Languages Act and may not be accessible to persons with disabilities. The information offered may be available only in the language(s) used by the sites in question. With respect to privacy, visitors should research the privacy policies of these non-government websites before providing personal information.

View trial details

Overview

Official protocol title:

A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTICENTER STUDY TO EVALUATE THE EFFECT OF EFPEGLENATIDE ON CARDIOVASCULAR OUTCOMES IN TYPE 2 DIABETES PATIENTS AT HIGH CARDIOVASCULAR RISK

Intervention/treatment:
SAR439977
Medical condition:
TYPE 2 DIABETES
Protocol code:
EFC14828
Control number:
214298
Status:
Closed
Approved:
April 12, 2018
Date Completed:
Trial phase:
Phase 3
For more information:
ClinicalTrials.gov - NCT03496298
This is an external link. The information is not authorized by the Government of Canada.

Eligibility

Sex: ALL
Age
18 Years and older
Accepts healthy volunteers: No

Contacts and locations

Contact
Name
Trial Transparency Team
Organization
Sanofi
Phone:
800-633-1610
Extension 6#
Sponsor
SANOFI-AVENTIS CANADA INC

Locations

Investigational Site Number 1240001
Barrie, L4N 7L3
Investigational Site Number 1240002
Brampton, L6S 0C6
Investigational Site Number 1240003
Vancouver, V5Y 3W2
Investigational Site Number 1240004
Concord, L4K 4M2
Investigational Site Number 1240005
Etobicoke, M9R 4E1
Investigational Site Number 1240006
Sherbrooke, J1L 0H8
Investigational Site Number 1240007
Calgary, T2H 2G4
Investigational Site Number 1240008
Montreal, H1M 1B1
Investigational Site Number 1240009
Victoriaville, G6P 6P6
Investigational Site Number 1240010
Québec, G1N 4V3
Investigational Site Number 1240011
Lévis, G6W 0M5
Investigational Site Number 1240012
Oshawa, L1J 2K1
Investigational Site Number 1240013
Toronto, M4G 3E8
Investigational Site Number 1240014
Montreal, H4A 2C6
Investigational Site Number 1240015
Oakville, L6M 1M1
Investigational Site Number 1240016
Pointe-Claire, H9R 4S3
Investigational Site Number 1240017
Montreal, H4N 2W2
Investigational Site Number 1240018
Burlington, L7M 1K9
Investigational Site Number 1240019
Red Deer, T4N 6V7
Investigational Site Number 1240020
Calgary, T2V 4J2
Investigational Site Number 1240021
Burlington, L7R 1E2
Investigational Site Number 1240022
Greater Sudbury, P3E 4H5
Investigational Site Number 1240023
Montreal, H4A 3T2
Investigational Site Number 1240024
Chicoutimi, G7H 7K9
Investigational Site Number 1240025
London, N5W 6A2
Investigational Site Number 1240026
Victoria, V8V 4A1
Investigational Site Number 1240027
Peterborough, K9J 0B2
Investigational Site Number 1240028
London, N6A 5R8
Investigational Site Number 1240029
Mirabel, J7J 2K8
Investigational Site Number 1240030
Ottawa, K2J 0V2
Investigational Site Number 1240031
Montreal, H1T 1C8

Results

See the results from the trial NCT03496298. This is an external link. The information is not authorized by the Government of Canada.

Date posted:
Did you find what you were looking for?